CN113766952B - 放射性药品的制造方法及放射性药品 - Google Patents

放射性药品的制造方法及放射性药品 Download PDF

Info

Publication number
CN113766952B
CN113766952B CN202080025813.XA CN202080025813A CN113766952B CN 113766952 B CN113766952 B CN 113766952B CN 202080025813 A CN202080025813 A CN 202080025813A CN 113766952 B CN113766952 B CN 113766952B
Authority
CN
China
Prior art keywords
radiopharmaceutical
radioactive
concentration
stabilizer
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080025813.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113766952A (zh
Inventor
吉井幸恵
张明荣
河村和纪
铃木寿
桥本裕辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes For Quantum Science and Technology
Original Assignee
National Institutes For Quantum Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes For Quantum Science and Technology filed Critical National Institutes For Quantum Science and Technology
Publication of CN113766952A publication Critical patent/CN113766952A/zh
Application granted granted Critical
Publication of CN113766952B publication Critical patent/CN113766952B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080025813.XA 2019-03-29 2020-02-14 放射性药品的制造方法及放射性药品 Active CN113766952B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019068873 2019-03-29
JP2019-068873 2019-03-29
PCT/JP2020/005830 WO2020202831A1 (ja) 2019-03-29 2020-02-14 放射性医薬の製造方法及び放射性医薬

Publications (2)

Publication Number Publication Date
CN113766952A CN113766952A (zh) 2021-12-07
CN113766952B true CN113766952B (zh) 2023-09-08

Family

ID=72667952

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080025813.XA Active CN113766952B (zh) 2019-03-29 2020-02-14 放射性药品的制造方法及放射性药品

Country Status (4)

Country Link
US (1) US20220175973A1 (https=)
JP (1) JP7576334B2 (https=)
CN (1) CN113766952B (https=)
WO (1) WO2020202831A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008709A1 (fr) * 1997-08-14 1999-02-25 Daiichi Radioisotope Laboratories, Ltd. Medicament radioactif stable
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
WO2011076825A1 (en) * 2009-12-23 2011-06-30 Bayer Schering Pharma Aktiengesellschaft Formulations suitable for pet imaging with hydrophobic pet agents
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
CN102458396A (zh) * 2009-04-15 2012-05-16 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
JP2017190354A (ja) * 2017-08-01 2017-10-19 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
TW201006517A (en) * 2008-05-22 2010-02-16 Asahi Kasei Medical Co Ltd Filtration method
RS55674B1 (sr) * 2008-12-31 2017-06-30 Avid Radiopharmaceuticals Inc Sinteza 18f-radio obeleženih stirilpiridina od tozilat prekursora i njihovih stabilnih farmaceutskih kompozicija
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
WO2013173004A2 (en) * 2012-04-10 2013-11-21 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
DE102012208375B4 (de) * 2012-05-18 2015-07-23 Zentralklinik Bad Berka Gmbh Satz und Verfahren zur Herstellung eines Radiopharmakons
JP6085810B2 (ja) * 2012-12-27 2017-03-01 日本メジフィジックス株式会社 放射性医薬及び医薬キット
US9956177B2 (en) * 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same
EP3418290A1 (en) * 2013-08-08 2018-12-26 CSL Ltd. Contaminant removal method
JP6226322B2 (ja) * 2013-10-23 2017-11-08 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008709A1 (fr) * 1997-08-14 1999-02-25 Daiichi Radioisotope Laboratories, Ltd. Medicament radioactif stable
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
CN102458396A (zh) * 2009-04-15 2012-05-16 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
WO2011076825A1 (en) * 2009-12-23 2011-06-30 Bayer Schering Pharma Aktiengesellschaft Formulations suitable for pet imaging with hydrophobic pet agents
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
JP2017190354A (ja) * 2017-08-01 2017-10-19 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis of 99mTc-Radiolabeled Uridine as a Potential Tumor Imaging Agent;H. M. Talaat et al;《RADIOCHEMISTRY》;20181231;摘要、第52页右栏第1段 *

Also Published As

Publication number Publication date
CN113766952A (zh) 2021-12-07
WO2020202831A1 (ja) 2020-10-08
JP7576334B2 (ja) 2024-10-31
US20220175973A1 (en) 2022-06-09
JPWO2020202831A1 (https=) 2020-10-08

Similar Documents

Publication Publication Date Title
KR100941210B1 (ko) 백금 유도체를 포함하는 제약 제제
EP2357166A1 (en) Auto magnetic metal salen complex compound
EP3766521B1 (en) Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition
CN103265560B (zh) 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用
EA010834B1 (ru) Пиридилзамещённые порфириновые соединения и способы их применения
Kumbhar et al. Light uncages a copper complex to induce nonapoptotic cell death
JP5873656B2 (ja) 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
CN113766952B (zh) 放射性药品的制造方法及放射性药品
JP2023062146A (ja) アスタチン溶液及びその製造方法
JP6170147B2 (ja) 癌治療
EP3199152B1 (en) Anti-cancer agent and method for killing cancer cells
EP4104833B1 (en) Ascorbic acid and quinone compound for cancer treatment
JP6085810B2 (ja) 放射性医薬及び医薬キット
Garabalino et al. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: Combined administration of BSH and BPA
JPWO2019087957A1 (ja) 放射性抗腫瘍剤
JP3348849B2 (ja) ３−ヒドロキシ−４−ピロンのガリウム錯体の医薬組成物
RU2024111522A (ru) Радиоактивный маркер и его соединение-прекурсор, способ их получения и их применение
WO2026008715A1 (en) Mitochondrially-targeted antioxidant compound for use in radiation therapy
Carpenter et al. The in vitro selective concentration of an 125I-iodinated compound in human tumor cells
WO2025251001A1 (en) N-(2-(-2-cyano-4-fluoropyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide tracer and uses in pet imaging
JP2023009974A (ja) ホウ素とヨウ素を含有する化合物又はその塩並びにそれらの用途
Kuykendall III et al. Radioprotectant Activity of 5‐Diethylsulfonamoylsalicylatocopper (II) in Gamma Irradiated Mice
JPS6054320A (ja) 腎疾患治療剤
WO2023250116A1 (en) Indocyanine green (icg) modification for treatment of liver cancer
WO2019236358A1 (en) Rubidium compounds for use in the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant